AUTHOR=Fan Qian-Ya , Zhang Xiao-Dong , Hu Ze-Di , Huang Shi-Shi , Zhu Shi-Guo , Chen Cai-Ping , Zhang Xiong , Wang Jian-Yong 

TITLE=Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease

JOURNAL=Frontiers in Neurology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.961758

DOI=10.3389/fneur.2022.961758

ISSN=1664-2295

ABSTRACT=<sec><title>Introduction</title><p>Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period.</p></sec><sec><title>Case presentation</title><p>We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.</p></sec><sec><title>Conclusion</title><p>The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.</p></sec>